Section Arrow
CVM.NYSE-M
- Cel-Sci Corp
Quotes are at least 15-min delayed:2021/06/24 11:46 EDT
Last
 23.2
+0.39 (+1.71%)
Day High 
23.4 
Prev. Close
22.81 
1-M High
25.55 
Volume 
258.68K 
Bid
23.21
Ask
23.26
Day Low
22.2568 
Open
22.6 
1-M Low
18.71 
Market Cap 
970.09M 
Currency USD 
P/E -- 
%Yield
10-SMA 21.88 
20-SMA 22.48 
50-SMA 21.67 
52-W High 40.91 
52-W Low 10.76 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.90/-0.82
Enterprise Value
982.96M
Balance Sheet
Book Value Per Share
0.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ORPHOrphazyme A/S7.84+0.4+5.38%--PE
ATOSAtossa Therapeutics7.9117+0.7617+10.65%--PE
ARAVAravive5.76+0.44+8.27%--PE
PIRSPieris Pharmaceuticals4.15+0.61+17.23%--PE
ACSTAcasti Pharma0.5629-0.0335-5.62%9.94PE
Quotes are at least 15-min delayed:2021/06/24 11:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune systemto fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.